Champions Oncology(CSBR) - 2025 Q3 - Quarterly Report

Revenue Performance - Oncology revenue for the three months ended January 31, 2025, was $17.0 million, a 41.8$12.0 million in the same period in 2024[99] - For the nine months ended January 31, 2025, oncology revenue reached $44.6 million, reflecting a growth of 23.3$36.2 million in the prior year[99] Cost Management - Total costs and operating expenses for the three months ended January 31, 2025, decreased by 14.1% to $12.5 million from$14.6 million in the prior year[98] - Research and development expenses for the three months ended January 31, 2025, were $1.7 million, a decrease of 21.4$2.2 million in the same period in 2024[106] - Cost of oncology revenue decreased by 15.7% to $6.6 million for the three months ended January 31, 2025, down from$7.8 million in the prior year[105] - General and administrative expenses decreased by $366,000, or 13.2$6.8 million, a decrease of $1.5 million, or 18.0$8.3 million in 2024[111] - The decrease in general and administrative expenses was primarily due to reductions in compensation and employee recruitment expenses[111] Financial Performance - The company reported an income from operations of $4.5 million for the three months ended January 31, 2025, compared to a loss of$2.6 million in the prior year[98] - For the nine months ended January 31, 2025, net cash provided by operating activities was $518,000, a significant improvement from a net cash used of$4.3 million in the same period of 2024[112] - Net cash used in investing activities was $136,000 for the nine months ended January 31, 2025, down from$839,000 in the prior year[113] - Net cash provided by financing activities was $202,000 for the nine months ended January 31, 2025, compared to a net cash used of$490,000 in the same period of 2024[114] Liquidity and Capital Needs - Cash on hand as of January 31, 2025, was approximately $3.2 million, indicating liquidity challenges[96] - The company may need to raise additional equity or debt capital in the near term to fund operations[97] Debt and Obligations - The company had an accumulated deficit of approximately$78.1 million as of January 31, 2025[96] - The company has no off-balance sheet debt or similar obligations[117] - There are no undisclosed transactions or obligations with related parties affecting the reported results[117] - The company does not guarantee any third-party debt[117] - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures[118]